An oral, three-mechanism gut-inflammation and intestinal-barrier ("leaky gut") support stack aimed at people with IBD-adjacent symptoms, food-reactivity, or post-NSAID/post-infectious gut irritation. The stacking rationale is division of labor: Larazotide is claimed to shore up the tight-junction barrier, KPV to calm the cytokine cascade already triggered, and BPC-157 to drive the underlying tissue repair — "prevent, calm, rebuild" rather than one compound doing all three jobs.
Why it matters
Three oral peptides are each claimed to target a different stage of gut damage: Larazotide to tighten the "leaky gut" barrier (the seals between gut-lining cells), KPV to calm inflammation, and BPC-157 to drive tissue repair — the "prevent, calm, rebuild" idea, not an established mechanism.
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
